SynAct Pharma AB

BATS-CHIXE:SYNACS Stock Report

Market Cap: SEK 764.2m

SynAct Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

BATS-CHIXE:SYNACS Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
19 Dec 25BuySEK 72,301Anders KronborgIndividual3,470SEK 20.84
19 Dec 25BuySEK 72,168Thomas JonassenIndividual3,529SEK 20.45

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of SYNACS?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders7,856,61314.8%
Institutions9,707,03818.2%
Private Companies16,373,63830.8%
General Public19,276,67936.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 24 shareholders own 63.78% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.8%
Avanza Fonder AB
6,300,906SEK 90.5m23.1%0.08%
10.6%
Sanos Bioscience A/S
5,653,006SEK 81.2m0%no data
9.96%
NBCD A/S
5,302,732SEK 76.1m0%no data
5.05%
Thomas Ringberg
2,687,190SEK 38.6m-1.2%no data
4.81%
Bioinvest Sverige Ab
2,559,852SEK 36.8m0%no data
4.78%
Thomas Jonassen
2,545,320SEK 36.6m15.9%no data
4.11%
Nordnet AB (publ)
2,186,540SEK 31.4m0%0.27%
4.06%
TJ Biotech Invest ApS
2,161,225SEK 31.0m0%no data
2.1%
Oliver Aleksov
1,119,935SEK 16.1m0%no data
1.7%
Handelsbanken Asset Management
906,614SEK 13.0m0%no data
1%
Or Invest A/S
533,302SEK 7.7m0%no data
1%
Johannes Schildt
533,302SEK 7.7m0%no data
0.71%
Jeppe Ovlesen
379,422SEK 5.4m9.43%no data
0.59%
SEB Funds AB
311,951SEK 4.5m0%no data
0.47%
Thomas Boesen
248,229SEK 3.6m4.95%no data
0.31%
Goodwind Holding GmbH
163,521SEK 2.3m-86.1%no data
0.25%
Sten Scheibye
132,093SEK 1.9m0%no data
0.15%
James Knight
77,452SEK 1.1m0%no data
0.14%
Anders Kronborg
76,155SEK 1.1m13.2%no data
0.063%
Bjorn Westberg
33,560SEK 482.0k0%no data
0.038%
Sten Sorensen
20,455SEK 293.7k17.5%no data
0.0056%
Mads Bjerregaard
3,000SEK 43.1k0%no data
0.0019%
State Street Global Advisors, Inc.
1,027SEK 14.7k-2.28%no data
0.00094%
Jeppe Andersen
500SEK 7.2k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/10 10:22
End of Day Share Price 2026/04/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SynAct Pharma AB is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Patrik LingDNB Carnegie
Jyoti PrakashEdison Investment Research
Carl RamaniusRedeye